RGC Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: November 07, 2025
Report Source: 2025 Annual Report
Regencell Bioscience Holdings Ltd. Stock Analysis RGC
Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company employs 10 full-time employees The company went IPO on 2021-07-16. The firm launches three liquid based standardized TCM formulae candidates for mild, moderate and severe ADHD and ASD patients.
Read More Regencell Bioscience Holdings Ltd (RGC) Chart
Key Statistics of Regencell Bioscience Holdings Ltd (RGC)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$26.51Volume
119.75KP/E Ratio (TTM)
-52 Week Range
Market Cap
13.48BAvg. Volume
104.24KDividend Yield
-Financial Metrics & Statements of Regencell Bioscience Holdings Ltd (RGC)
Community-Curated Collections with Regencell Bioscience Holdings Ltd (RGC) ( With RGC )
View AllCommunity-Curated Collections are thoughtfully selected groups of stocks or assets, curated by investors and experts based on shared themes, values, or investment strategies.
FAQ's for Regencell Bioscience Holdings Ltd (RGC)
- According to Musaffa’s Shariah screening methodology, Regencell Bioscience Holdings Ltd (RGC) is currently classified as NOT HALAL as of November 2025. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.